Crizotinib is an oral tyrosine kinase inhibitor targeting ALK, ROS1, and MET, used to treat certain non-small cell lung cancers. It works by inhibiting the proliferation of cancer cells that express these kinases. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Crizotinibum and Xalkori. Its PubChem CID is 11626560.
Crizotinib
| CAS No | 877399-52-5 |
|---|---|
| Molecular Formula | C21H22Cl2FN5O |
| Molecular Weight | 450.34 g/mol |
| Synonyms | 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Crizotinib is an oral tyrosine kinase inhibitor targeting ALK, ROS1, and MET, used to treat certain non-small cell lung cancers. It works by inhibiting the proliferation of cancer cells that express these kinases.
The listed CAS number is 877399-52-5.
The listed molecular formula is C21H22Cl2FN5O.
The listed molecular weight is 450.34 g/mol.
3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine.
The source lists Crizotinibum and Xalkori.